All AbMole products are for research use only, cannot be used for human consumption.
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.
| CAS Number | 2229047-91-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[4] Adrian Minson, et al. Leuk Lymphoma. Glofitamab CD20-TCB bispecific antibody
| Related CD20 Products |
|---|
| Obinutuzumab
Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20. |
| Ofatumumab
Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation. |
| Rituximab
Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD. |
| Ripertamab
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL). |
| Zuberitamab
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
